US OptionsDetailed Quotes
OGN241018C17500
- 1.26
- -0.37-22.70%
15min DelayClose Oct 2 16:00 ET
1.45High1.26Low
1.45Open1.63Pre Close6 Volume174 Open Interest17.50Strike Price794.00Turnover36.36%IV0.97%PremiumOct 18, 2024Expiry Date1.08Intrinsic Value100Multiplier16DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type0.8042Delta0.1966Gamma14.57Leverage Ratio-0.0142Theta0.0059Rho11.72Eff Leverage0.0107Vega
Organon & Co Stock Discussion
Sign in to post a comment
$Bank of America (BAC.US)$ : ”...You buy some right here, you buy some maybe if it breaks 40. I think this company is selling very inexpensively, and it’s a good one.”
$Illumina (ILMN.US)$ : “No. No Illumina. I like Danaher.”
$Constellation Energy (CEG.US)$ : “This is a solar play that is a very good company. It’s up a huge amount versus a lot of other stocks...I think you buy some, please hold on to it, do not sell it.”
$Meta Platforms (META.US)$ : “I thin...
$Illumina (ILMN.US)$ : “No. No Illumina. I like Danaher.”
$Constellation Energy (CEG.US)$ : “This is a solar play that is a very good company. It’s up a huge amount versus a lot of other stocks...I think you buy some, please hold on to it, do not sell it.”
$Meta Platforms (META.US)$ : “I thin...
From YouTube
3
1
Organon's low P/E ratio is due to its predicted growth being less than the broader market. Shareholders accept this as they anticipate future earnings won't bring any pleasant surprises. The share price is unlikely to rise significantly soon under these conditions.
4
1
Analysts show increased negativity towards the business following recent results, reflected in a minor decrease in next year's EPS estimates. Despite predicted earnings decline, Organon's valuation is not expected to be significantly affected, but growth is anticipated to lag behind the industry.
1
1
Seeking Alpha analysts are growing more bullish on the Merck spinoff, despite Wall Street's neutral stance. Analysts Leo Nelissen and Gen Alpha highlight OGN's attractive yield as a reason for their Buy ratings.
1
Despite the company's payout ratio not posing an immediate concern, the significant decline in earnings per share raises concerns about Organon from a dividend perspective. Therefore, caution is advised for potential investors considering Organon for its upcoming dividend.
2
U.S. stocks were lower after the close on Tuesday, as losses in the Basic Materials, Financials and Technology sectors led shares lower.
At the close in NYSE, the Dow Jones Industrial Average fell 0.45%, while the S&P 500 index lost 0.42%, and the NASDAQ Composite index lost 0.79%.
The best performers of the session on the Dow Jones Industrial Average were Amgen Inc ( $Amgen (AMGN.US)$ ), which rose 3.11% or 7.86 points t...
At the close in NYSE, the Dow Jones Industrial Average fell 0.45%, while the S&P 500 index lost 0.42%, and the NASDAQ Composite index lost 0.79%.
The best performers of the session on the Dow Jones Industrial Average were Amgen Inc ( $Amgen (AMGN.US)$ ), which rose 3.11% or 7.86 points t...
4
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after market closed (gaps range from large to small):
Gap Ups
1. $Novo-Nordisk A/S (NVO.US)$ - up 13.4%
2. $Eli Lilly and Co (LLY.US)$ - up 10.5%
3. $James Hardie Industries (JHX.US)$ - up 10.1%
4. $New York Times (NYT.US)$ - up 3.3%
5. $POSCO (PKX.US)$ - up 2.9%
6. $Fox Corp-B (FOX.US)$ - up 2.8%
7. $Fox Corp-A (FOXA.US)$ - up 2.8%
8. $West Pharmaceutical Services (WST.US)$ - up 2.5...
Gap Ups
1. $Novo-Nordisk A/S (NVO.US)$ - up 13.4%
2. $Eli Lilly and Co (LLY.US)$ - up 10.5%
3. $James Hardie Industries (JHX.US)$ - up 10.1%
4. $New York Times (NYT.US)$ - up 3.3%
5. $POSCO (PKX.US)$ - up 2.9%
6. $Fox Corp-B (FOX.US)$ - up 2.8%
7. $Fox Corp-A (FOXA.US)$ - up 2.8%
8. $West Pharmaceutical Services (WST.US)$ - up 2.5...
+17
10
Loop Capital Starts Micron at Buy Ahead of DRAM Bottom
Loop Capital analyst Charles Park initiated coverage of $Micron Technology (MU.US)$ with a Buy rating and $70 price target. The analyst expects DRAM fundamentals to bottom in the first half of 2023 and notes that the shares "typically bottoming a couple of quarters ahead."
AppLovin Initiated With an Outperform at Wedbush
Wedbush analyst Nick McKay initiated coverage of $Applovin (APP.US)$ with an O...
Loop Capital analyst Charles Park initiated coverage of $Micron Technology (MU.US)$ with a Buy rating and $70 price target. The analyst expects DRAM fundamentals to bottom in the first half of 2023 and notes that the shares "typically bottoming a couple of quarters ahead."
AppLovin Initiated With an Outperform at Wedbush
Wedbush analyst Nick McKay initiated coverage of $Applovin (APP.US)$ with an O...
13
1
No comment yet
Money Thrill : Not Only a solar player, "Our generation fleet of nuclear, hydro, wind, and solar generation facilities powers"![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")